Foundayo Tracker: What to Track on the GLP-1 Pill (2026)
This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.
Quick answer
A Foundayo tracker logs your daily dose, weight trend, protein & side effects. Learn exactly what to track on the once-daily oral GLP-1 pill orforglipron and why.
Foundayo (orforglipron) is Eli Lilly's once-daily oral GLP-1 receptor agonist, approved by the FDA on April 1, 2026 for chronic weight management in adults with obesity — or overweight plus a weight-related condition — alongside a reduced-calorie diet and more activity (FDA news release; Eli Lilly).
What makes it different from Wegovy or Ozempic is simple but changes everything about tracking: it is a pill you take every day, not a weekly injection.
That means there is no injection site to rotate — but there is a daily dose that is easy to forget, which makes consistent record-keeping the whole game.
This guide covers what to track on Foundayo, why each item matters, and how to turn it into a two-minute daily habit. It is neutral and educational: you can do all of it on paper.
An app just automates the parts people skip.
If you want the general framework first, start with our complete GLP-1 tracker app guide, then come back here for the Foundayo specifics.
01
Why tracking matters on Foundayo specifically
Three things about Foundayo make tracking more than a nice-to-have:
It is a daily pill, so a miss is easy.
With a once-weekly injection you have one dose to remember; with a daily tablet you have seven times as many chances to forget. A simple daily check — took it, yes or no — is the single most valuable thing you can log on Foundayo.
The dose escalates slowly, on 30-day steps.
Foundayo starts very low and steps up no sooner than every four weeks to limit stomach side effects. Logging which strength you are on, and when you stepped up, keeps you synced to the plan and gives your prescriber an exact history.
Results and side effects are non-linear.
Weight comes off in fits and plateaus, and nausea tends to spike right after each dose increase. Only a trend — not a single day — tells you what is actually happening.
02
What to track on Foundayo (and why each one matters)
Here is the core Foundayo dataset. Use it as your checklist whether you track on paper, in a spreadsheet, or in an app.
Note how it differs from an injectable tracker: the headline field is daily adherence, not injection-site rotation.
Daily dose and the Foundayo titration schedule
Foundayo is a once-daily tablet that can be taken any time of day, with or without food or water — a practical advantage over some oral medicines that require timing rules (Eli Lilly).
It is deliberately started low and increased no sooner than every 30 days to reduce gastrointestinal side effects.
Per the FDA label, the schedule is 0.8 mg once daily to start → after ≥30 days 2.5 mg → after ≥30 days 5.5 mg, with further increases to 9 mg, 14.5 mg, or 17.2 mg as tolerated; maintenance runs from 5.5 mg up to a maximum of 17.2 mg once daily (DailyMed label; Foundayo dosing, Lilly).
Because the strength changes on a calendar, logging which mg you are on and the date you stepped up is the most useful thing you can record.
Your prescriber decides your maintenance dose — a clean dose log makes that conversation faster.
Missed doses on a daily pill
Because Foundayo is once daily, a single missed day is generally less disruptive than a missed weekly shot — but do not take two doses to make up for one.
The label-specific rule to know is about longer gaps: if you miss 7 or more consecutive daily doses, your prescriber may re-start dose escalation at a lower strength to limit stomach side effects (DailyMed label).
A tracker that logs a simple daily check makes both cases obvious — you can see at a glance whether you skipped one day or drifted for a week. Always follow your own label and prescriber.
Weight, measurements, and progress photos
Weight is the headline number for a Foundayo weight loss tracker, but it is noisy day to day.
In Lilly's phase 3 ATTAIN-1 trial, adults on Foundayo lost on average up to roughly 11% of body weight at 72 weeks, versus about 2% on placebo, alongside diet and activity (Eli Lilly).
Those are trial averages over more than a year — so weigh in at the same time (typically morning, after the bathroom, before eating) and let the trend line, not a single reading, tell the story.
Waist measurements and progress photos every 2–4 weeks capture body-composition change the scale hides, which matters most exactly when the number stalls.
Protein, food, and protecting muscle
This is the most under-appreciated part of any GLP-1 journey.
Because these medicines sharply reduce appetite, a meaningful share of the weight you lose can be lean body mass — analyses of GLP-1 weight-loss trials have reported roughly 30–40% of lost weight as lean mass (note some of this is water and organ tissue, not only skeletal muscle) (review in Frontiers / PMC).
Muscle protects your metabolism and long-term results. Two trackable habits do the heavy lifting:
- Protein. Aim for a high-protein target at each meal (many clinicians suggest distributing protein across the day). When appetite drops, protein is usually the first thing to fall — so logging it keeps it front of mind.
- Resistance training. Strength work is the strongest defense against muscle loss on a GLP-1; log your sessions like you log your dose.
Side effects — normal vs. red flag
The most common Foundayo side effects are gastrointestinal: nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain.
These usually appear or worsen right after a dose increase and settle as your body adapts.
Foundayo also carries a boxed warning for thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid cancer or with Multiple Endocrine Neoplasia syndrome type 2; rare but serious risks such as pancreatitis and gallbladder disease need prompt medical assessment (FDA news release).
Logging what you felt, how severe, and how many days since your last dose step-up turns a vague "I've felt off" into a clear pattern.
For the full symptom-by-symptom breakdown, see our guide to GLP-1 side effects.
03
How to build a Foundayo tracking routine in 6 steps
You do not need a complicated system — you need a repeatable one. This takes under two minutes a day.
- 1
Set a daily pill reminder.
Foundayo can be taken any time, but a consistent time and a recurring alert build the habit and prevent misses.
- 2
Log the dose right after taking it.
Tap "taken," record the mg strength, and note the date whenever you step up.
- 3
Weigh in on fixed days.
Choose 1–3 mornings a week, same conditions, and read the trend — not the daily noise.
- 4
Track protein and water daily.
A quick tap per meal is enough to keep muscle protection on track.
- 5
Note side effects when they happen.
Record the symptom, severity, and days since your last dose increase.
- 6
Photo every 2–4 weeks and review before each visit.
Same lighting, same angle — and bring your dose log and side-effect timeline to your clinician.
04
Do you need a Foundayo app, or is a notebook fine?
Honestly, any tracking beats none — a Foundayo diary in a notebook works.
What an app adds is the automation of the parts people forget: the daily reminder, the trend line that smooths daily weight noise, and a side-effect timeline you can hand to your clinician.
Foundayo does not ship with a dedicated companion app, so most people use a general GLP-1 or wellness tracker.
If you want your dose log living next to the daily habits that protect your results — protein, movement, hydration, weight and body-composition trends — a wellness app like HAVIT is a natural home for it.
Compare a few options in our best GLP-1 tracker apps guide and pick what you will actually keep using; consistency matters far more than the brand.
05
Related guides
06
Why HAVIT — Medication + Behavior Change, in One App
GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.
Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.
That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).
HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.
Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).
Manage the medicine and the muscle — together. Start with HAVIT →
What to track on Foundayo (and why each one matters)
| What to track | Why it matters | How often |
|---|---|---|
| Daily dose taken (yes/no) + time | Adherence is the core metric for a once-daily pill; a consistent time builds the habit | Every day |
| Current strength (mg) & step-up date | Foundayo escalates on ≥30-day steps; confirms you are on plan and prevents an early jump | At each dose change |
| Body weight | The primary outcome; the trend reveals plateaus and metabolic adaptation | 1–3× per week, same time of day |
| Waist / measurements | Catches fat loss the scale misses, especially while preserving muscle | Every 1–2 weeks |
| Protein intake (grams) | Protects lean muscle mass, which is at risk during rapid weight loss | Daily |
| Water / hydration | Eases the constipation and nausea common in the first weeks | Daily |
| Side effects & severity | Separates normal adaptation from red-flag symptoms needing a doctor | As they occur |
| Progress photos | Visual proof of body-composition change when the scale stalls | Every 2–4 weeks |
| Refill / pill supply | A daily tablet runs out on a predictable date; avoids a coverage gap | Monthly |
Frequently asked questions
What is a Foundayo tracker?
What is Foundayo, and how is it different from Wegovy or Ozempic?
What should I track on Foundayo?
What is the Foundayo dose schedule I should log?
What happens if I miss a Foundayo dose?
How often should I weigh myself on Foundayo?
Why is protein tracking so important on Foundayo?
Is there an official Foundayo tracking app?
What is Havit?
Havit is an AI health companion for weight loss that protects muscle.
Unlike calorie-only trackers, Havit connects AI body-composition estimates, nutrition, hydration, sleep, steps, cycle, mood, and GLP-1 medication in one daily routine — so progress is measured by body composition, not just the number on the scale. Daily missions turn established behavior-change techniques into small repeatable actions, drawing on expertise from professionals formerly at Juvis Diet, one of Korea’s leading metabolic clinics.
In Havit’s own analysis of 1,090 GLP-1 users, people who logged consistently built stronger habits than the general user base. Read the GLP-1 Habit Report
Havit works with or without GLP-1 medication. It is a wellness app, not a medical device; body-composition results are estimates.
Continue in the App
Personalized wellness with your own data
References
- U.S. Food & Drug Administration — news release on the approval of Foundayo (orforglipron): first new molecular entity under the National Priority Voucher program; indication and boxed warning for thyroid C-cell tumors (April 1, 2026). fda.gov fda.gov
- Eli Lilly and Company — "FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions": indication, oral once-daily use, ATTAIN-1 weight-loss results. investor.lilly.com investor.lilly.com
- DailyMed (U.S. National Library of Medicine) — FOUNDAYO (orforglipron) tablet label: dosing/titration, missed-dose (7-consecutive-dose) guidance, boxed warning. dailymed.nlm.nih.gov dailymed.nlm.nih.gov
- Foundayo (Eli Lilly) — How to take Foundayo: once-daily, any time, with or without food; dosing steps. foundayo.lilly.com foundayo.lilly.com
- Cleveland Clinic — GLP-1 agonists: uses, how they work, and side effects. my.clevelandclinic.org my.clevelandclinic.org
- Frontiers in Clinical Diabetes and Healthcare (via PMC) — GLP-1 agonists, lean-mass loss, and the role of exercise and protein. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
- All medical claims verified against the cited FDA news release, Eli Lilly materials, and the FOUNDAYO label as of July 2026. Foundayo is a newly approved medicine; re-review at least every 12 months or sooner if the FDA label changes.*
